These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 16215309)

  • 1. Predictive value of the international prostate symptom score for positive prostate needle biopsy in the low-intermediate prostate-specific antigen range.
    Kefi A; Irer B; Ozdemir I; Tuna B; Goktay Y; Yorukoğlu K; Esen A
    Urol Int; 2005; 75(3):222-6. PubMed ID: 16215309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of lower urinary tract symptoms is an independent predictor for cancer at prostate biopsy, but prostate-specific antigen is not: results from a prospective series of 569 patients.
    Porter CR; Latchamsetty KC; Coogan CL; Kim J
    Clin Prostate Cancer; 2005 Jun; 4(1):50-4. PubMed ID: 15992462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of prostate volume measurement using transabdominal ultrasonography for the improvement of prostate-speci fi c antigen-based cancer detection.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    Int J Urol; 2005 Oct; 12(10):881-5. PubMed ID: 16323981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship between screening by stratifying cases into groups on prostate specific antigen level and the positive rate of transrectal ultrasound guided systematic sextant prostate biopsy].
    Cao XL; Gao JP; Han G; Tang J; Hong BF
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):372-5. PubMed ID: 16638344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of prostate specific antigen (PSA), PSA density, free-to-total PSA ratio and a new formula (prostate malignancy index) for detecting prostate cancer and preventing negative biopsies in patients with normal rectal examinations and intermediate PSA levels.
    Dinçel C; Caşkurlu T; Taşçi AI; Cek M; Sevin G; Fazlioğlu A
    Int Urol Nephrol; 1999; 31(4):497-509. PubMed ID: 10668945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there any association between the severity of lower urinary tract symptoms and the risk of biopsy-detectable prostate cancer in patients with PSA level below 20 ng/ml in multi-core prostate biopsy?
    Oh JJ; Jeong SJ; Jeong CW; Byun SS; Hong SK; Choe G; Lee SE
    Prostate; 2013 Jan; 73(1):42-7. PubMed ID: 22585359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels.
    Tarcan T; Ozveri H; Biren T; Türkeri L; Akdas A
    Int J Urol; 1997 Jul; 4(4):362-7. PubMed ID: 9256325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of prostate volume measured by transrectal and abdominal echography and its implication for the measurement of the PSA density for the diagnosis of prostate cancer].
    Rodríguez-Patrón Rodríguez R; Mayayo Dehesa T; Lennie Zucharino A; González Galán A
    Arch Esp Urol; 2002 Sep; 55(7):797-806. PubMed ID: 12380308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density.
    Bangma CH; Kranse R; Blijenberg BG; Schröder FH
    Urology; 1995 Dec; 46(6):779-84. PubMed ID: 7502415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low AUA symptom score independently predicts positive prostate needle biopsy: results from a racially diverse series of 411 patients.
    Porter CR; Kim J
    Urology; 2004 Jan; 63(1):90-4. PubMed ID: 14751356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer?
    Ohori M; Dunn JK; Scardino PT
    Urology; 1995 Nov; 46(5):666-71. PubMed ID: 7495118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
    Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
    BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSA density improves prediction of prostate cancer.
    Verma A; St Onge J; Dhillon K; Chorneyko A
    Can J Urol; 2014 Jun; 21(3):7312-21. PubMed ID: 24978363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen adjusted for the transition zone volume as a second screening test: a prospective study of 248 cases.
    Kang SH; Bae JH; Park HS; Yoon DK; Moon DG; Kim JJ; Cheon J
    Int J Urol; 2006 Jul; 13(7):910-4. PubMed ID: 16882054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations.
    Gohji K; Nomi M; Egawa S; Morisue K; Takenaka A; Okamoto M; Ohori M; Fujii A
    Cancer; 1997 May; 79(10):1969-76. PubMed ID: 9149025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
    Rahardjo D; Kamil ST; Pakasi LS
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
    Garzotto M; Hudson RG; Peters L; Hsieh YC; Barrera E; Mori M; Beer TM; Klein T
    Cancer; 2003 Oct; 98(7):1417-22. PubMed ID: 14508828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.
    Kumar V; Jagannathan NR; Kumar R; Thulkar S; Gupta SD; Hemal AK; Gupta NP
    NMR Biomed; 2007 Feb; 20(1):11-20. PubMed ID: 16894640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
    Men S; Cakar B; Conkbayir I; Hekimoglu B
    J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.